Development code · Small Molecule
BNC-210
BNC-210 is a development code for BNC210 (soclenicant), developed by Neuphoria Therapeutics, Inc..
- Status
- Phase 2 for Post-traumatic stress disorder
- Mechanism
- alpha7 nAChR NAM
- Developer
- Neuphoria Therapeutics, Inc.
Programs
- BNC210 (soclenicant) for Post-traumatic stress disorderPhase 2Suspended
- BNC210 (soclenicant) for Social anxiety disorderDiscontinuedDiscontinued
Also known as
- BNC210
- IW-2143
- soclenicant
- 1020634-41-6
- 6-[(2,3-dihydro-1H-inden-2-yl)amino]-1-ethyl-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4(1H)-one